The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that “target” those changes. This combination of a tumor with a mutation and a drug that aims at that mutation is called a “match.” There are two steps for participants in this study.
   
The first step is called screening. The purpose of screening is to review tests that have been done on the tumor tissue to see if there is a mutation that makes participants eligible for one of the MATCH treatment trials. Eligibility for this trial may have been determined in part on the basis of a laboratory-developed test that has not been reviewed or approved by the U.S. Food and Drug Administration (FDA). 
   
If it is confirmed that a mutation in the test report makes someone eligible for a MATCH treatment trial, they will have the opportunity to participate in the second step, which is the investigational treatment part of the study.

The study doctor will tell each participant about the drug and explain the specifics of getting that drug, including the potential side effects and benefits of the drug. Participants will then receive the drug and will be monitored to see what its effects are on your tumor. The study doctor will outline the total length of study participation with each participant.